Is it bad, is it good, or is IgG4 just misunderstood?
Repeated doses of mRNA vaccines for COVID-19 result in increased proportions of anti-spike antibodies of the IgG4 subclass.
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022.
Vaccination coverage in the EU/EEA during autumn 2023 campaigns
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn/winter campaign in the EU/EEA, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
Respiratory Viruses in Wastewater Compared with Clinical Samples, Leuven, Belgium
Since the COVID-19 pandemic began, wastewater-based surveillance has been used to track circulation levels of SARS-CoV-2.
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike
Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism
Research shows that the procoagulant state of PBMC could aid in the early detection of PE in COVID-19 ICU patients. When combined with the end-tidal to ETCO2 – PaCO2 gradient, these tests could improve the early detection of PE in the ICU.
mRNA SARS-CoV-2 Vaccination Before vs During Pregnancy and Omicron Infection Among Infants
Infants younger than 6 months are at risk of severe SARS-CoV-2 infection.
The European Respiratory Virus Surveillance Summary (ERVISS)
This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and severe acute respiratory syndrome coronavirus 2 for the EU/EEA and the WHO European Region
SARS-CoV-2 evolution in the Omicron era
Since SARS-CoV-2 BA.5 (Omicron) emerged and spread in 2022, Omicron lineages have markedly diversified.
The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research
In the last three years, extensive research has demonstrated the safety and efficacy of COVID-19 vaccines. These vaccines have played a critical role in reducing mortality and hospitalization rates.
Variant-adapted COVID-19 booster vaccines
Current vaccines should be tailored to combat future SARS-CoV-2 variants.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
